#398 ‒ AMA #86: GLP-1 RAs and muscle loss: new data, better questions, and how to preserve muscle during weight loss

We discuss:

• The evolution of GLP-1 receptor agonists from diabetes drugs to breakthrough weight-loss therapies [1:45];
• Early concerns about lean mass loss with GLP-1 receptor agonists and the limitations of clinical trial data [3:45];
• How newer research has changed the understanding of lean mass loss on GLP-1 receptor agonists and why DEXA measurements can misrepresent muscle loss [6:15];
• Comparing lean mass loss across semaglutide, tirzepatide, and traditional weight-loss interventions [10:30];
• Comparing lean mass loss from GLP-1 receptor agonists with bariatric surgery, and whether these drugs cause muscle loss beyond normal expectations from substantial weight loss [13:15];
• The limited evidence regarding the timing of lean mass loss during GLP-1 therapy and the implications for exercise and nutrition strategies [16:00];
• Body composition changes after stopping GLP-1 receptor agonists: weight regain, fat regain, and lean mass recovery [17:45];
• Why lean mass measurements are an imperfect proxy for muscle health and function [21:45];
• The effects of GLP-1 receptor agonists on bone mineral density, fracture risk, and the importance of resistance training [23:00];
• Do GLP-1 receptor agonists directly cause muscle loss or simply mimic the effects of calorie restriction? [26:00];
• Why strength and physical function often improve despite lean mass loss on GLP-1 receptor agonists [28:00];
• Who is most at risk for lean mass loss during GLP-1–induced weight loss? [34:45];
• Intramuscular fat (IMAT), DEXA limitations, and the challenge of measuring true muscle loss [37:00];
• Preserving muscle while losing weight: resistance training, protein intake, and emerging research on preserving muscle during GLP-1–induced weight loss [39:00];
• Resistance-training principles for preserving lean mass during GLP-1–induced weight loss [43:45];
• Managing side effects and prioritizing protein intake while training on GLP-1 receptor agonists [46:15];
• Retatrutide: early evidence on its effects on weight loss, lean mass, and muscle function, as well as the limitations of the data being collected in ongoing clinical trials [48:00];
• The risks of using gray-market retatrutide before FDA approval [52:15];
• Key takeaways [54:30]; and
• More.

The evolution of GLP-1 receptor agonists from diabetes drugs to breakthrough weight-loss therapies [1:45]

Introduction to the AMA Topic: GLP-1 Agonists

• Previous The Drive episodes on GLP-1s:
  • First episode occurred approximately five years earlier with Bob Kaplan.
    • At the time, there was relatively little public interest in the topic.
  • A follow-up episode roughly 18 months later generated significantly more attention.

Why has public interest in GLP-1 drugs increased so dramatically between those episodes?

Initial Use of Liraglutide (2014)

• Peter began using GLP-1 agonists clinically in 2014.
• His first experience was with liraglutide.
• He found the results relatively underwhelming:
  • Limited clinical impact.
  • High cost.
  • Logistical challenges associated with treatment.
• As a result, he largely abandoned its use at that time.

Emergence of Semaglutide

• By the time of the first GLP-1 podcast episode:
  • Peter and his team were already observing the effects of semaglutide.
  • Semaglutide appeared dramatically different from earlier GLP-1 drugs.
• Peter describes semaglutide as a:
  • “Third-generation” GLP-1 agonist.
  • “Step function change” compared to earlier agents.

Recognition of Semaglutide’s Significance

• Peter recalls that by approximately Q4 2020:
  • His team recognized that semaglutide represented a major advance over previous GLP-1 therapies.
• Suggests there was a lag between clinical recognition of semaglutide’s significance and the public awareness and adoption.

Transition from Diabetes Drug to Weight-Loss Drug

Change in Clinical Relevance

• Earlier GLP-1 agonists were primarily viewed as:
• Diabetes medications.
• Relatively niche therapies.

Semaglutide changed the conversation because:

• It demonstrated unprecedented weight-loss effects.
• It was being evaluated in people without diabetes.
• This dramatically expanded the potential patient population.

Why Public Interest Exploded

• Weight loss—not diabetes treatment—was the catalyst for widespread interest.
• Semaglutide’s effectiveness in obesity transformed GLP-1 drugs into a mainstream topic.
• Peter suggests this marked the beginning of the current GLP-1 era.

Regulatory Focus at the Time

• Peter notes that early FDA evaluations were focused primarily on weight-loss outcomes.
• Less attention was being paid to:
  • Body composition.
  • Lean mass retention.
  • Muscle preservation.
• This focus on weight loss rather than body composition helped shape the early narrative surrounding GLP-1 therapies.

Early concerns about lean mass loss with GLP-1 receptor agonists and the limitations of clinical trial data [3:45]

Early Concerns About Lean Mass Loss on GLP-1 Agonists

Initial Clinical and Trial Observations

• Early clinical experience and trial data suggested that people losing weight on GLP-1 agonists were losing an unexpectedly large amount of lean mass.
• The amount of lean mass loss appeared greater than what was typically observed with:
  • Traditional caloric restriction
  • Dietary restriction
  • Time-restricted eating
• Peter notes there is some nuance (“an asterisk”) to that comparison, which will be explored later.

The “One-to-One” Lean Mass Concern

• Early observations suggested an approximately 1:1 ratio of fat loss to lean mass loss.

{end of show notes preview}